These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20458349)

  • 1. A need for evidence-based clinical practice guidelines for the use of heparins in the elderly.
    Gouin-Thibault I; Siguret V; Pautas E
    Clin Interv Aging; 2010 Apr; 5():119-21. PubMed ID: 20458349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing and monitoring of low-molecular-weight heparins in special populations.
    Duplaga BA; Rivers CW; Nutescu E
    Pharmacotherapy; 2001 Feb; 21(2):218-34. PubMed ID: 11213859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure.
    Stratta P; Karvela E; Canavese C; Quaglia M; Lazzarich E; Fenoglio R; Pergolini P; Bellomo G; Cena T; Magnani C
    Curr Med Chem; 2009; 16(23):3028-40. PubMed ID: 19689280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing low molecular weight heparins in kidney disease.
    Saltiel M
    J Pharm Pract; 2010 Jun; 23(3):205-9. PubMed ID: 21507815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
    Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
    Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
    Cestac P; Bagheri H; Lapeyre-Mestre M; Sié P; Fouladi A; Maupas E; Léger P; Fontan B; Massip P; Montastruc JL
    Drug Saf; 2003; 26(3):197-207. PubMed ID: 12580648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How and when to monitor a patient treated with low molecular weight heparin.
    Boneu B; de Moerloose P
    Semin Thromb Hemost; 2001 Oct; 27(5):519-22. PubMed ID: 11668422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004.
    Siguret V; Pautas E; Gouin I
    Curr Opin Pulm Med; 2004 Sep; 10(5):366-70. PubMed ID: 15316433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
    Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
    J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.
    Samama MM
    Drugs Aging; 2011 Mar; 28(3):177-93. PubMed ID: 21329400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are low-molecular-weight heparins safe and effective in children? A systematic review.
    Klaassen ILM; Sol JJ; Suijker MH; Fijnvandraat K; van de Wetering MD; Heleen van Ommen C
    Blood Rev; 2019 Jan; 33():33-42. PubMed ID: 30041977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using low molecular weight heparin in special patient populations.
    Lim W
    J Thromb Thrombolysis; 2010 Feb; 29(2):233-40. PubMed ID: 19902146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis.
    Wu T; Xia X; Chen W; Fu J; Zhang J
    J Clin Pharm Ther; 2020 Aug; 45(4):602-608. PubMed ID: 32449992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.